Journal
BLOOD
Volume 120, Issue 22, Pages 4304-4310Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-03-419879
Keywords
-
Categories
Funding
- NHLBI/National Institutes of Health [N01-HB-07150, N01-HB-07151, N01-HB-07152, N01-HB-07153, N01-HB-07154, N01-HB-07155, N01-HB-07156, N01-HB-07157, N01-HB-07158, N01-HB-07159, N01-HB-07160]
- Best Pharmaceuticals for Children Act
- NICHD
Ask authors/readers for more resources
The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninety-three subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials.gov). (Blood. 2012;120(22):4304-4310)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available